Yahoo
Swiss - Delayed Quote CHF

Santhera Pharmaceuticals Holding AG (SANN.SW)

16.50 +0.60 (+3.77%)
At close: 5:30:56 PM GMT+2
Chart Range Bar
Loading chart for SANN.SW
  • Previous Close 15.90
  • Open 15.70
  • Bid --
  • Ask --
  • Day's Range 15.70 - 16.50
  • 52 Week Range 9.38 - 18.84
  • Volume 77,869
  • Avg. Volume 67,644
  • Market Cap (intraday) 251.56M
  • Beta (5Y Monthly) -0.28
  • PE Ratio (TTM) --
  • EPS (TTM) -3.78
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 27.50

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

www.santhera.com

93

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/18/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

SANN.SW
30.95%
MSCI WORLD (^990100-USD-STRD)
11.57%

1-Year Return

SANN.SW
20.61%
MSCI WORLD (^990100-USD-STRD)
0.00%

3-Year Return

SANN.SW
102.45%
MSCI WORLD (^990100-USD-STRD)
71.42%

5-Year Return

SANN.SW
18.92%
MSCI WORLD (^990100-USD-STRD)
60.45%

Analyst Insights

View More

Analyst Price Targets

25.00
27.50 Average
16.50 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 8/14/2026
  • Market Cap

    242.41M

  • Enterprise Value

    268.92M

  • Trailing P/E

    --

  • Forward P/E

    175.44

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.67

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.48

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -63.79%

  • Return on Assets (ttm)

    -15.64%

  • Return on Equity (ttm)

    -620.02%

  • Revenue (ttm)

    77.19M

  • Net Income Avi to Common (ttm)

    -49.24M

  • Diluted EPS (ttm)

    -3.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    22.44M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -35.63M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: